These results demonstrate that loss-of-function editing of FADS2 or ACSL4 confers competitive growth advantage under imetelstat pressure, identifying ACSL4 and FADS2 as mediators of imetelstat efficacy in AML. Here, ACSL4 is linked to acute myeloid leukemia.